Epidemiology of antimicrobial resistance and its clinical, economic and humanistic outcomes in developing countries
Article Sidebar
Main Article Content
Abstract
The important therapeutic role played by antimicrobial agents is seriously being threatened by the continually increasing antibacterial resistance (AMR) across the globe. Efforts at stemming the increment is grossly suboptimal in most developing countries. Epidemiology of the commonly encountered bacterial isolates and their respective susceptivity/resistance patterns is highly essential in supply chain decision making, patient management and in policy formulation. The most prevalent resistant bacterial isolates in Nigeria include Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa and Klebsiella pneumoniae among others. For instance, the incidence of methicillin resistant S. aureus is skyrocketing. It has increased from less than 2.0% in 2005 to more than 40.0% in 2020 across the country. In addition, resistance to affordable antimicrobial agents is gradually overwhelming the fragile health care system mostly being financed from out-of-pocket expenses. Treatment costs of resistant isolates is huge and not sustainable, apart from its impacts on disease complications, morbidity, mortality and human capital development. Overall, it grossly reduces health related quality of life. In consonant with the global pledge of the World Health Assembly, improved awareness and an understanding of its implications should be a priority. Strengthening diagnosis and surveillance activities as related to AMR is imperative. The primary health care (PHC) basic roles, which include provision of portable water, sanitation, immunization, and nutrition need to be strengthened as long advocated. Research into new antimicrobial agents as well as evidence-based re-purposing/rational usage of the existing ones should also be topical at all levels. Standard Treatment Guidelines and drug formularies equally need to be reviewed at regular intervals to include updated resistant/susceptibility patterns. Formulating adequate legal frame work and policy to facilitate implementation of strategies are of utmost important as well. And lastly, there should be relevant incentives to encourage implementation of AMR related stewardship activities and its sustainability.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
How to Cite
Share
References
WHO (2019) Monitoring and evaluation of the global action plan on antimicrobial resistance. Framework and recommended indicators 30 May 2019 https://www.who.int/publications/i/item/monitoring-and-evaluation-of-the-global-action-plan-onantimicrobial-resistance
World Health Organization (WHO). (2021) Anti-bacteria Resistance. Fact Sheets. https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance
World Health Organization (WHO) Global action plan on antimicrobial resistanc January 2016.
World Health Organization, Food and Agriculture Organization of the United Nations & World Organization for Animal Health (FAO, OIE, and WHO) (2019).
Akova M (2016) Epidemiology of antimicrobial resistance in bloodstream infection. Virulence 2016, Vol 7 (3) 252-266. http://dx.doi.org/10.1080/21505594.2016.1159366.
Collins English Dictionary. Copyright © HarperCollins Publishers
Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. Journal Infect Diseases 2008; 197:1079-81; PMID: 18419525; http://dx.doi.org/10.1086/533452
Peterson LR. Bad bugs, no drugs: no ESCAPE revisited. Clinical Infection Diseases 2009; 49:992; PMID:19694542; http://dx.doi.org/10.1086/60553
De Oliveira DMP, Forde BM, Kidd TJ, Harris PNA, Schembri MA, Beatson SA, Paterson DL, Walker MJ (2020). Antimicrobial Resistance in ESKAPE Pathogens. Clinical Microbiol Rev 2020 May 13;33(3): e00181-19. doi: 10.1128/CMR.00181-19. Print 2020 Jun 17.
Adesida S, Bockens H, Babajide B, Kehinde A, Snijders S, van Leeuwen W, et al. A major epidemic clone of Staphylococus aureus in Nigeria. Micro Drug Resist, 2005 Summer;11(2):115-121.
Suleiman IA, Bamiro BS and Tayo F (2012) Cost Effectiveness of three drugs for the treatment of S. aureus in Nigeria. International Journal of Clinical Pharmacy 34:739-745. DOI 10.1007/s11096-012-9671-x
Ghebremedhin B, Olugbosi MO, Raji AM, Layer F, Bakare RA, Ko ¨nig B, Ko ¨nig W. Emergence of a community-associated methicillin-resistant Staphylococcus aureus strain with a unique resistance profile in Southwest Nigeria. Journal Clinical Microbiol. 2009;47(9):2975-80. (Epub 2009 Jul 1).
Terry Alli OA, Ogbolu DO, Akorede E, Onemu OM, Okanlawon BM. Distribution of mecA gene amongst Staphylococcus aureus isolates from South western Nigeria. African Journal Biomed Research. 2011; 14(1):9-16.
Abubakar U, Sulaiman ASS (2018). Prevalence, trend and antimicrobial susceptibility of Methicillin Resistant Staphylococcus aureus in Nigeria: a systematic review. Journal of Infection and Public Health Volume 11, Issue 6, November-December 2018, Pages 763 - 770.
https://doi.org/10.1016/j.jiph.2018.05.013
Ibadin EE, Enabulele IO, Muinah F.(2017) Prevalence of mecA gene among staphylococci from clinical samples of a tertiary hospital in Benin City, Nigeria. African Health Science. 2017 Dec;17(4):1000-1010. doi: 10.4314/ahs.v17i4.7.
Adeiza SS,Onaolapo JA, Olayinka BO.(2020) Prevalence, risk-factors, and antimicrobial susceptibility profile of methicillin-resistant Staphylococcus aureus (MRSA) obtained from nares of patients and staff of Sokoto state-owned hospitals in Nigeria. GMS Hyg Infection Control 2020 Oct 12;15:Doc25. doi: 10.3205/dgkh000360. eCollection 2020
Olorunfemi PO, Onaolapo JA, Ibrahim YKE (2020) Prevalence and antibiotic susceptibility of community acquired methicillin resistantStaphylococcus aureus from healthy students of University of Jos. Journal of Pharmacy & Bioresources Vol. 17 no. 2, pp. 131-141 (September 2020) DOI: 10.4314/jpb.v17i2.7
Sadiq A, Samad M, Saddam, Basharat N,Ali S, Roohullah, Saad Z, Nawaz Khan A, Ahmad Y, Khan A, Khan J Methicillin-Resistant Staphylococcus aureus (MRSA) in Slaughter Houses and Meat Shops in Capital Territory of Pakistan During 2018-2019. Front Microbiol . 2020 Sep 28;11:577707. doi: 10.3389/fmicb.2020.577707. eCollection 2020.
Akpan SN, Odeniyi OA, Adebowale OO, Alarape SA, Adeyemo OK, (2020). Antibiotic resistance profile of Gram-negative bacteria isolated from Lafenwa abattoir effluent and its receiving water (Ogun River) in Abeokuta, Ogun state, Nigeria. Onderstepoort J Vet Res. 2020; 87(1): 1854 . Published online 2020 Sep 15. doi: 10.4102/ojvr.v87i1.1854
Olowo-okere A, Ibrahim YKE, Nabti LZ, Olayinka BO. (2020). High prevalence of multidrug-resistant Gram-negative bacterial infections in Northwest Nigeria. Germs. 2020 Dec; 10(4): 310-321.ublished online 2020 Dec 28. doi: 10.18683/germs.2020.1223 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7 811856
Suleiman IA, Tayo F (2013) Usefulness of Routine Antibacterial Susceptibility Testing for Resistance Surveillance in Lagos Metropolis. African Journal of Biomedical Research 16(January 2013) 11-17
Kibret M and Abera B (2011) Antimicrobial susceptibility patterns of E. coli from clinical sources in northeast Ethiopia. Afr Health Sci. 2011 Aug; 11(Suppl 1): S40-S45. doi: 10.4314/ahs.v11i3.70069
Olorunmola FO, Kolawole DO, Lamikanra A (2013) Antibiotic Resistance and Virulence Properties in Escherichia Coli Strains from Cases of Urinary Tract Infections. African Journal Infect Diseases. 2013; 7(1): 1-7.doi: 10.4314/ajid.v7i1.1
Okeke I N, Lamikanra A, Czeczulin, Dubovsky F, Kaper J B, Nataro J P. Heterogenous virulence of Enteroagregative Escherichia coli strains isolated from children in Southwest Nigeria. Journal Infect Diseases. 2000;181(1):252-260.
World Health Organization (2021). Antimicrobial Resistancehttps://www.who.int/news-room/factsheets/detail/antimicrobial-resistance. Accessed 21st March 2022.
National Institute of Allergy and Infectious Diseases (NIAID 2011). Causes of Antimicrobial Resistance. https://www.niaid.nih.gov/research/antimicrobialresistance-causes
Chukwu EE, Oladele DA, Awoderu OB, Afocha EE,
Lawal AG, Abus-alam I, Ogunsola FT, Audu RA (2020). A national survey of public awareness of antimicrobial resistance in Nigeria. Antitimicrob Resist Infect Control. 2020; 9: 72 doi: 10.1186/s13756-020-00739-0
Federal Ministries of Agriculture, Environment and Health. (2017) Antimicrobial Use and Resistance in Nigeria, Situation Analysis and Recommendations.
Natural Selection https://en.wikipedia.org/wiki/Natural_selection. Accessed on 20th March 2022
Gaude GS. (2015). Preventing bacterial resistance: Need of the hour. Indian Journal of Health Sciences and Biomedical Research (KLEU), 8(1), 1
Andersson DI, Balaban NQ, Baquero F, Courvalin P, Glaser P, Gophna U, & Tønjum T (2020). Antibiotic resistance: turning evolutionary principles into clinical reality. FEMS Microbiology Reviews, 44(2), 171-188.
Bello-López JM, Cabrero-Martínez OA, IbáñezCervantes G, Hernández-Cortez C, PelcastreRodríguez LI, Gonzalez-Avila LU, & Castro-Escarpulli G (2019). Horizontal gene transfer and its association with antibiotic resistance in the genus Aeromonas spp. Microorganisms, 7(9), 363.
McCann E, Srinivasan CA, DeRyke A, Ye G, DePestel DD, Murray J, et al. (2018). Carbapenem nonsusceptible gram-negative pathogens in ICU and non-ICU settings in US hospitals in 2017: A multicenter study. Open Forum of Infectious Diseases
Shaikh S, Fatima J, Shakil S, Rizvi SD, & Kamal MA (2015). Antibiotic resistance and extended spectrum beta-lactamases: Types, epidemiology and treatment. Saudi journal of Biological Sciences, 22(1), 90-101.
Ballal M. (2016). Trends in antimicrobial resistance among enteric pathogens: a global concern. Antibiotic Resistance, 63 - 92.
Aslam B, Wang W, Arshad MI, Khurshid M, Muzammil S, Rasool MH, & Baloch Z (2018). Antibiotic resistance: a rundown of a global crisis. Infection and drug resistance, 11, 1645.
Toma A, & Deyno S (2015). Overview on mechanisms of antibacterial resistance. International Journal of Research in Pharmacy and
Biosciences, 2(1), 27-36.
Thaden JT, Li Y, Ruffin F, Maskarinec SA, Hill-Rorie JM, Wanda LC, et al. (2017). Increased costs associated with bloodstream infections caused by multidrugresistant gram-negative bacteria are due primarily to patients with hospital-acquired infections. Antimicrobial Agents Chemotherapy; 61: e01709-16
Suleiman IA and Tayo F (2012) Cost of TherapyEvaluation in The Treatment of Sexually Transmitted Infections in a Nigerian Teaching
Hospital. Journal of Pharmaceutical Health Services Research. 3: 115-120 doi/10.1111/j.1759-8893.2011.00067.
Suleiman IA and Tayo F (2010). Comparative costs of Antibacterial Usage in Sexually Transmitted Infections in a Nigerian Teaching Hospital Tropical Journal of Pharmaceutical Research 9(6):549-555.
CDC (2013). Antibiotic Resistance Threats in the United States. A vailable on https://www.cdc.gov/drugresistance/biggest_thre
ats.html
O'Neill J (chair). Review on antimicrobial resistance: tackling a crisis for the health and wealth of nations. 2014. Available at http://amr-review.org/
O'Neill J. (2021). Tackling drug-resistant infections globally: final report and recommendations. Available at; https://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf
Choksi A, Sifri Z, Cennimo D, Horng H (2019). Global Contributors to Antibiotic Resistance. Journal of Global Infectious Diseases; 11(1):36-42doi:10.4103/jgid.jgid_110_18
Dadgostar P. (2019). Antimicrobial resistance: Implications and costs. Infection and Drug Resistance 12: 3903-3910.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6929930/
Founou RC, Founou LL, Essack SY (2017). Clinical and economic impact of antibiotic resistance in developing countries: A systematic review and meta-analysis. PLoSOne. 12: e0189621doc:10.1371/journal.pone.0189621.
Shrestha P, Cooper BS, Coast J, Oppong R, Thuy NDT, Podha T, Celhay O, Guerin PJ, Wertheim H, Lubell Y (2018). Enumerating the economic cost of antimicrobial resistance per antibiotic consumed to inform the evaluation of interventions affecting their use. Antimicrobial Resistance and Infection Control; 7:98
Cecchini M, Langer J, Slawomirski L (2015). Antimicrobial resistance in G7 countries and beyond: Economic issues, policies and options for action. Paris, France: The Organisation for Economic Co-operation and Development.
Chatterjee S, Poonawala H, Jain y (2018). Drugresistant tuberculosis: Is India ready for the challenge? Commentary. BMJ Global Health; 3:971
Xu L, Sun X, Ma X (2017). Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae. Annals of Clinical Microbiology and Antimicrobials. 16(1), 1-12
Acevski S, Nakov Z (2017). Need for implementation of pharmacoeconomics in healthcare system, case of analysis of antibiotic consumption in Republic of Macedonia for 2016. Macedonian Pharmaceutical Bulletin. 63(2) 11-20
Nigeria Center for Disease Control (NCDC), Federal Ministries of Agriculture, Environment and Health. Antimicrobial Use and Resistance in Nigeria: situation analysis and recommendations. 2017. Available from https://ncdc.gov.ng›themes›common›docs›protocols.
https://ncdc.gov.ng/themes/common/docs/protocols/56_1510840387.pdf accessed on 13th March 2022.
World Bank (2015). The World in 2050 Will the shift in global economic power continue? https://www.pwc.com/gx/en/issues/the-economy/assets/world-in-2050-february-2015.pdf
Antonanzas F, Goossens H (2019). The economics of antibiotic resistance: a claim for personalized treatments. The European Journal of Health Economics. 20, 483-485
Suleiman IA and Tayo F (2011) Economic Evaluation of Antibacterial Usage in Ear, Nose and Throat infections in a Nigerian Teaching Hospital International Journal of Health Research, 4(1): 45-51
Carmeli Y, Eliopoulos G, Mozaffari E, Samore M (2002). Health and economic outcomes of vancomycin-resistant enterococci. Archives of
Internal Medicine 162:2223-2228.
Suleiman IA, Bamiro BA, Mendie UE (2014). Cost Effectiveness of Six Drugs for the treatment of Pseudomonas aeruginosa Infections in Nigeria. International Journal of Pharmacy and Pharmaceutical Sciences 6 (5) 239-244
Monitoring and evaluation of the global action plan on antimicrobial resistance: framework and recommended indicators. Sixty-eighth World Health Assembly (WHA68.7), 26 may 2015, Agenda Item 15.1, Global action plan on antimicrobial resistance.
Abera B, Kibret M, & Mulu W. Knowledge and beliefs on antimicrobial resistance among physicians and nurses in hospitals in Amhara Region, Ethiopia. BMC Pharmacol Toxicol 15, 26 (2014). https://doi.org /10.1186/2050-6511-15-26. https://bmcpharmacoltoxicol.biomedcentral.com/articles/10.1186/2050-6511-15-26
World Bank. 2017. "Drug-Resistant Infections: A Threat to Our Economic Future." Washington, DC: World Bank. License: Creative Commons Attribution CC BY 3.0 IGO www.worldbank.org
Suleiman IA and Tayo F (2013). Cost Minimization Analysis of Antibacterial Therapy in a Developing Country. West African Journal of Pharmacy 24 (1) 14-21.
Sy CL, Chen PY, Cheng CW, Huang LJ, Wang CH, Chang TH, Wang FD, et al. (2022). Recommendations and Guidelines for the Treatment of Infections due to Multidrug Resistant Organisms. Journal of Microbiology, Immunology and Infection. PII: S1684- 1182 (22) 00025-1DOI:
https://doi.org /10.1016/j.jmii.2022.02.001 Reference: JMII 1508